Literature DB >> 24735919

Genomic dark matter sheds light on EVI1-driven leukemia.

Richard P Koche1, Scott A Armstrong2.   

Abstract

The orchestration of transcriptional programs depends on proper gene-enhancer pairing. While much remains to be learned about this process in normal development, two recent studies in Cell (Gröschel and colleagues) and this issue of Cancer Cell (Yamazaki and colleagues) highlight how the genomic rearrangement of an enhancer plays a causal role in the onset of a leukemogenic program.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24735919      PMCID: PMC4046890          DOI: 10.1016/j.ccr.2014.03.031

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  10 in total

1.  Differential expression of the translocated and the untranslocated c-myc oncogene in Burkitt lymphoma.

Authors:  A ar-Rushdi; K Nishikura; J Erikson; R Watt; G Rovera; C M Croce
Journal:  Science       Date:  1983-10-28       Impact factor: 47.728

2.  EVI-1 modulates leukemogenic potential and apoptosis sensitivity in human acute lymphoblastic leukemia.

Authors:  M Konantz; M C André; M Ebinger; M Grauer; H Wang; S Grzywna; O C Rothfuss; S Lehle; O S Kustikova; H R Salih; R Handgretinger; F Fend; C Baum; L Kanz; L Quintanilla-Martinez; K Schulze-Osthoff; F Essmann; C Lengerke
Journal:  Leukemia       Date:  2012-07-25       Impact factor: 11.528

Review 3.  Lessons from the cancer genome.

Authors:  Levi A Garraway; Eric S Lander
Journal:  Cell       Date:  2013-03-28       Impact factor: 41.582

4.  Master transcription factors and mediator establish super-enhancers at key cell identity genes.

Authors:  Warren A Whyte; David A Orlando; Denes Hnisz; Brian J Abraham; Charles Y Lin; Michael H Kagey; Peter B Rahl; Tong Ihn Lee; Richard A Young
Journal:  Cell       Date:  2013-04-11       Impact factor: 41.582

Review 5.  Enhancer malfunction in cancer.

Authors:  Hans-Martin Herz; Deqing Hu; Ali Shilatifard
Journal:  Mol Cell       Date:  2014-03-20       Impact factor: 17.970

6.  Highly recurrent TERT promoter mutations in human melanoma.

Authors:  Franklin W Huang; Eran Hodis; Mary Jue Xu; Gregory V Kryukov; Lynda Chin; Levi A Garraway
Journal:  Science       Date:  2013-01-24       Impact factor: 47.728

Review 7.  The role of EVI1 in myeloid malignancies.

Authors:  Carolyn Glass; Michael Wilson; Ruby Gonzalez; Yi Zhang; Archibald S Perkins
Journal:  Blood Cells Mol Dis       Date:  2014-02-01       Impact factor: 3.039

8.  A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression.

Authors:  Hiromi Yamazaki; Mikiko Suzuki; Akihito Otsuki; Ritsuko Shimizu; Emery H Bresnick; James Douglas Engel; Masayuki Yamamoto
Journal:  Cancer Cell       Date:  2014-04-03       Impact factor: 31.743

Review 9.  Master regulatory GATA transcription factors: mechanistic principles and emerging links to hematologic malignancies.

Authors:  Emery H Bresnick; Koichi R Katsumura; Hsiang-Ying Lee; Kirby D Johnson; Archibald S Perkins
Journal:  Nucleic Acids Res       Date:  2012-04-05       Impact factor: 16.971

10.  A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia.

Authors:  Stefan Gröschel; Mathijs A Sanders; Remco Hoogenboezem; Elzo de Wit; Britta A M Bouwman; Claudia Erpelinck; Vincent H J van der Velden; Marije Havermans; Roberto Avellino; Kirsten van Lom; Elwin J Rombouts; Mark van Duin; Konstanze Döhner; H Berna Beverloo; James E Bradner; Hartmut Döhner; Bob Löwenberg; Peter J M Valk; Eric M J Bindels; Wouter de Laat; Ruud Delwel
Journal:  Cell       Date:  2014-04-03       Impact factor: 41.582

  10 in total
  1 in total

1.  Mutational spectrum of myeloid malignancies with inv(3)/t(3;3) reveals a predominant involvement of RAS/RTK signaling pathways.

Authors:  Stefan Gröschel; Mathijs A Sanders; Remco Hoogenboezem; Annelieke Zeilemaker; Marije Havermans; Claudia Erpelinck; Eric M J Bindels; H Berna Beverloo; Hartmut Döhner; Bob Löwenberg; Konstanze Döhner; Ruud Delwel; Peter J M Valk
Journal:  Blood       Date:  2014-11-07       Impact factor: 22.113

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.